newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in